Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma

NCT04432506 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04432506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
July 27, 2020
Completion date
May 28, 2024
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, recurrent diffuse large b-cell lymphoma, recurrent high grade b-cell lymphoma, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory high grade b-cell lymphoma, refractory primary mediastinal (thymic) large b-cell lymphoma, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma